You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
北海康成(01228.HK)MaralixibatLIVMARLI在治療進行性家族性肝內膽汁淤積症3期試驗中取得積極頂線數據
北海康成(01228.HK)宣佈,其合作夥伴Mirum製藥(MIRM.US)發佈的LIVMARLI(maralixibat)口服溶液在治療進行性家族性肝內膽汁淤積症(PFIC)安全性和有效性的第3期MARCH研究評估中,取得了積極頂線數據。 PFIC已被納入2018年由國家衛健委聯合五部委發佈的《第一批罕見病目錄》。北海康成擁有maralixibat(CAN108)在大中華區開發與商業化的獨家授權,用於治療包括膽道閉鎖(BA)、阿拉傑裏綜合徵(ALGS)和PFIC在內的三種罕見肝病。北海康成監督CAN108在中國開展治療BA的 II期EMBARK研究。根據海南博鰲樂城國際醫療旅遊先行區的先行先試政策,CAN108已獲批在區內用於治療ALGS。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account